Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
01 4월 2024 - 9:00PM
Daxor Corporation (Nasdaq:
DXR), the global leader in blood volume measurement
technology, today announces it will be exhibiting at the American
College of Cardiology (ACC.24) at the Georgia World Congress Center
in Atlanta, GA, April 6 – 8, 2024.
“ACC.24 is considered the premier
cardiology exposition in the Americas, offering a prime opportunity
for Daxor to broaden its reach within the entire cardiovascular
community,” said Michael Feldschuh, Daxor’s CEO and President.
“This conference presents an ideal platform for engaging with
healthcare providers for whom effective volume management poses a
significant challenge. Our blood volume analysis (BVA) technology
provides 98% accurate, actionable data to optimize treatment plans
and personalize care, improving outcomes while reducing duration
and cost of care.”
The Company will be exhibiting at Booth
#2312.
Register for the event HERE.
About American College of
Cardiology
The American College of Cardiology (ACC) is
the global leader in transforming cardiovascular care and improving
heart health for all. As the preeminent source of professional
medical education for the entire cardiovascular care team since
1949, ACC credentials cardiovascular professionals in
over 140 countries who meet stringent qualifications and leads in
the formation of health policy, standards, and
guidelines. Through its world-renowned family of JACC
Journals, NCDR registries, ACC Accreditation Services, global
network of Member Sections, CardioSmart patient resources and more,
the College is committed to ensuring a world where science,
knowledge and innovation optimize patient care and
outcomes. Learn more at www.ACC.org.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the only diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing trials in the areas of
heart failure treatment with support from the NIH and is under
contract developing analyzers to improve combat casualty care with
the U.S. Department of Defense. Daxor's mission is to advance
healthcare by enabling optimal fluid management with blood volume
analysis. Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign up to
receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr. Managing Partner,
CORE IR516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Daxor (NASDAQ:DXR)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024